特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
921984

症候群マルチプレックス診断の世界市場:成長率、動向および予測

Syndromic Multiplex Diagnostic Market - Growth, Trends, and Forecast (2020 - 2025)

出版日: | 発行: Mordor Intelligence LLP | ページ情報: 英文 115 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=106.45円
症候群マルチプレックス診断の世界市場:成長率、動向および予測
出版日: 2020年01月01日
発行: Mordor Intelligence LLP
ページ情報: 英文 115 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界の症候群マルチプレックス診断市場について調査分析し、市場概要、市場力学、市場区分、地域別の市場分析、競合情勢、主要企業などについて、体系的な情報を提供しています。

目次

第1章 イントロダクション

  • 調査の成果
  • 調査の前提条件
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概況
  • 市場成長要因
    • 正確で迅速な結果に対する需要の増加
    • 迅速に治療を受けられる機会と抗生物質による副作用の軽減
  • 市場阻害要因
    • 医師による不本意と、熟練した専門家の不足
    • 無症候性症例の検出不能
  • ポーターのファイブフォース分析
    • 新規参入の脅威
    • バイヤー/消費者の交渉力
    • サプライヤーの交渉力
    • 代替製品の脅威
    • 競争力の強さ

第5章 市場セグメンテーション

  • 症候群タイプ別
    • 呼吸器
    • 胃腸
    • 中枢神経系
    • その他
  • エンドユーザー別
    • 病院
    • 診断研究所
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ地域
    • 南米

第6章 競合情勢

  • 会社概要
    • BIOMERIEUX SA
    • Qiagen
    • Luminex Corporation
    • Applied BioCode
    • Akonni Biosystems
    • Mesa Biotech
    • Abbott
    • Accelerate Diagnostic
    • Diagenode Diagnostics
    • Hologic

第7章 市場機会および将来動向

目次
Product Code: 67634

Market Overview

The syndromic multiplex diagnostic market studied was anticipated to grow with a CAGR of nearly 7.2% during the forecast period. The major factors attributing to the growth of the syndromic multiplex diagnostic market are a rise in the number of infectious cases and diseases and higher incidences of side effects associated with the use of antibiotics which demand the necessity of diagnostics. Thus, owing to its ability to address the rising needs of the patients and clinicians like utilization of lesser resources, enhanced accuracy of results led the syndromic multiplex diagnostic market to grow throughout the forecast period. For instance, in May 2018, according to the World Health Organization, the leading cause of deaths recorded worldwide was lower respiratory infections necessitating the high requirement for advanced diagnostic equipment which fuel the global syndromic multiplex diagnostic market.

Scope of the Report

The syndrome is a collection of abnormal signs and symptoms that are often associated with a specific disease where identification of the specific causative agent is difficult in order to take precautions in advance or give appropriate treatment for the patients. The syndromic multiplex diagnostic test employs testing of various pathogens in a single test reaction, helps healthcare providers to deliver efficient medications in proper time by minimizing uncertainty and mistakes that occur while testing of an infection. The syndromic multiplex diagnostic test gives more accurate, realistic and comprehensive results in critical care.

Key Market Trends

Respiratory by Type of Syndrome is Expected to Hold the Major Market Share in the Syndromic Multiplex Diagnostic Market

  • Respiratory syndromes account for the largest share of the syndromic multiplex diagnostics market and expected to continue the same throughout the forecast period. This dominance mainly due to factors such as the higher demand due to the rapid spread of infections along with the launch of new products with USFDA approvals in the segment that contributes to its major revenue share in the global market.
  • By End-user, hospitals account for the largest share due to the availability of all resources at a single facility. Also, the reduction of the overall stay of patients for treatment in hospitals with the reduced procedural time along with minimal or no uncertainties, and errors in the treatments is expected to fuel the market during the forecast period.

North America Dominates the Market and Expected to do Same in the Forecast Period.

North America has been the primary market for the syndromic multiplex diagnostic market and is expected to hold a significant share in global revenue owing to the adoption of advanced technologies and the availability of improved healthcare infrastructure, and also rise in R&D laboratories resultant.

Europe has been the second-largest market for syndromic multiplex diagnostic market, where the market is fueled by the increased healthcare expenditure, and preference of patients for novel treatment procedures.

Globally, the syndromic multiplex diagnostics market is expected to witness the fastest growth in the Asia-Pacific region during the forecast period due to the higher demand for treatments with widespread infections, rise in government support to spread the healthcare awareness among people about various infections in the region.

Competitive Landscape

The Global Syndromic multiplex diagnostic market is moderately competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some prominent players are launching new products, while others are distributing the products, making acquisitions and partnerships to increase their footprints in the market. For instance, in June 2019, Biomerieux received approval for their Novel TruDiagnosis System by Food and Drug Administration (FDA) which is specially designed for the diagnosis of multiple infections. The unique microfluidic design in a single chamber result in a much faster workflow and a cost-effective consumable for multiplexed testing as compared to traditional technologies. Some of the companies which are currently dominating the market are BIOMERIEUX SA, Luminex Corporation, QIAGEN, Applied BioCode, and Akonni Biosystems.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Demand for Accurate and Rapid Results
    • 4.2.2 Quick Access to the Treatment and Reduction of the Adverse Reactions of Antibiotics
  • 4.3 Market Restraints
    • 4.3.1 Reluctance by Doctors and lack of Skilled Professional
    • 4.3.2 The Inability in Detecting Asymptomatic Cases
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type of Syndrome
    • 5.1.1 Respiratory
    • 5.1.2 Gastrointestinal
    • 5.1.3 Central Nervous System
    • 5.1.4 Others
  • 5.2 By End-user
    • 5.2.1 Hospitals
    • 5.2.2 Diagnostics Laboratories
    • 5.2.3 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 BIOMERIEUX SA
    • 6.1.2 Qiagen
    • 6.1.3 Luminex Corporation
    • 6.1.4 Applied BioCode
    • 6.1.5 Akonni Biosystems
    • 6.1.6 Mesa Biotech
    • 6.1.7 Abbott
    • 6.1.8 Accelerate Diagnostic
    • 6.1.9 Diagenode Diagnostics
    • 6.1.10 Hologic

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.